15

30

## **CLAIMS**

That which is claimed is:

- 5 1. An isolated proteinaceous molecule having canine PTH1 activity, wherein said proteinaceous molecule comprises an amino acid sequence of SEQ ID NO:2, or an amino acid sequence of SEQ ID NO:2 with one or more conservative substitutions therein.
- 10 2. An isolated proteinaceous molecule according to claim 1, wherein said amino acid sequence has zero to three conservative substitutions therein.
  - 3. An isolated proteinaceous molecule according to claim 1, wherein said amino acid sequence comprises an amino acid sequence of SEQ ID NO:2.
  - 4. An isolated DNA molecule encoding a proteinaceous molecule according to claim 1.
- 5. An isolated DNA molecule encoding a proteinaceous molecule 20 according to claim 3.
  - 6. A recombinant expression vector comprising a DNA molecule according to claim 4.
- 25 7. A cell transformed by an expression vector according to claim 6.
  - 8. A cell according to claim 7, wherein said cell is that of a prokaryote.
  - 9. A cell according to claim 7, wherein said cell is that of a eukaryote.
  - 10. A cell according to claim 9, wherein said eukaryote is yeast.
  - 11. A cell according to claim 9, wherein said eukaryote is a mammal.

- 12. A cell according to claim 11, which is a CHO cell.
- 13. A method of producing a proteinaceous molecule having an activity of canine PTH1, which comprises culturing a cell according to claim 7 for a time sufficient to produce said proteinaceous molecule.
  - 14. A pharmaceutical composition comprising the proteinaceous molecule according to claim 1 and a pharmaceutically acceptable carrier therefor.

10

5

- 15. A pharmaceutical composition comprising the proteinaceous molecule according to claim 3 and a pharmaceutically acceptable carrier therefor.
- 16. A specific binding partner that selectively binds to the proteinaceous15 molecule according to claim 1.
  - 17. A method of discovering ligands for the canine PTH1 protein, said method comprising the steps of:
    - a) combining a test substance with the proteinaceous molecule according to claim 1;
    - b) measuring specific binding between said test substance and said proteinaceous molecule; and
    - c) classifying as a ligand said test substance if it binds to said proteinaceous molecule.

25

20

- 18. A method of discovering modulators of canine PTH1 protein activity, said method comprising the steps of:
  - a) combining a test substance with the proteinaceous molecule according to claim 1;

30

- b) measuring the activity of said proteinaceous molecule in the presence and absence of said test substance and; and
- c) classifying said test substance as a modulator of canine PTH1 activity if it modulates the activity of said proteinaceous molecule.